A new study shows that coating neural prosthetic implants with the anti-inflammatory drug dexamethasone helps reduce the body’s immune response and scar tissue formation.

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

An international research team, including scientists from the Institut de Neurociències at the Universitat Autònoma de ...

An international research team, including scientists from the Institut de Neurociències at the Universitat Autònoma de ...

On the left, implant without dexamethasone; on the right, with treatment. As observed, the drug reduces the size of the fibrous capsule that forms around the implant after its surgical insertion into ...

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with relapsed or refractory multiple myeloma.

Acute subdural hematoma (ASDH) is a common brain lesion resulting from traumatic brain injuries and is associated with high ...

Patients with subacute subdural hematoma (sASDH) do not have an optimal non-surgical therapeutic strategy. In this study, ...

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

Dexamethasone is often used during radiation therapy (RT). Higher doses are used at the onset of and during RT with lower doses at the end of RT (Hempen, Weiss, & Hess, 2002).

The usual but empirical initial dose in brain tumor patients is an intravenous bolus of 10 mg of dexamethasone, followed by a maintenance dose of 4 mg given by the intravenous (IV) route every 6 ...

Background: Croup remains a common respiratory problem presenting to emergency departments. A single oral treatment of oral dexamethasone results in improved outcome. Prednisolone has similar ...